Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Murray, Heather M
Buckley, Brendan M
de Craen, Anton J M
Seshasai, Sreenivasa Rao Kondapally
McMurray, John J
Freeman, Dilys J
Jukema, J Wouter
Macfarlane, Peter W
Packard, Chris J
Stott, David J
Westendorp, Rudi G
Davis, Barry R
Pressel, Sara L
Marfisi, Rosa Maria
Maggioni, Aldo P
Pedersen, Terje R
Cook, Thomas J
Gotto, Antonio M
Clearfield, Michael B
Downs, John R
Ray, Kausik K
AffiliationBritish Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. firstname.lastname@example.org
Diabetes Mellitus, Type 2
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Randomized Controlled Trials as Topic
MetadataShow full item record
CitationStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. 2010, 375 (9716):735-42 Lancet
AbstractTrials of statin therapy have had conflicting findings on the risk of development of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of published and unpublished data whether any relation exists between statin use and development of diabetes.
We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1994 to 2009, for randomised controlled endpoint trials of statins. We included only trials with more than 1000 patients, with identical follow-up in both groups and duration of more than 1 year. We excluded trials of patients with organ transplants or who needed haemodialysis. We used the I(2) statistic to measure heterogeneity between trials and calculated risk estimates for incident diabetes with random-effect meta-analysis.
We identified 13 statin trials with 91 140 participants, of whom 4278 (2226 assigned statins and 2052 assigned control treatment) developed diabetes during a mean of 4 years. Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials. Meta-regression showed that risk of development of diabetes with statins was highest in trials with older participants, but neither baseline body-mass index nor change in LDL-cholesterol concentrations accounted for residual variation in risk. Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes.
Statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.
- Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.
- Authors: Zhou Y, Yuan Y, Cai RR, Huang Y, Xia WQ, Yang Y, Wang P, Wei Q, Wang SH
- Issue date: 2013 Aug
- Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
- Authors: Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P
- Issue date: 2007 Feb
- Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
- Authors: Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK
- Issue date: 2011 Jun 22
- Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.
- Authors: Cai R, Yuan Y, Zhou Y, Xia W, Wang P, Sun H, Yang Y, Huang R, Wang S
- Issue date: 2014
- Risk of incident diabetes among patients treated with statins: population based study.
- Authors: Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM
- Issue date: 2013 May 23